Joint Lab of Perceptive Neural Network and Disease

    The joint lab of perceptive neural network and disease is co-built by Guangdong Institute of Intelligent Science and Technology and SIMR (Zhuhai) Biotechnology Co., Ltd. The goal of the joint lab is to establish a platform for translational drug development in neurological diseases including chronic pain, depression, epilepsy, Alzheimer’s disease, etc. Under the collaboration with domestic and foreign hospitals, the lab aims to build a clinical database of neurological diseases and utilize artificial intelligence algorithms for patient data analysis to identify novel markers. The lab is dedicated to set up a more accurate standard of diseases classification and a precise path for innovative drug discovery.

Joint Directors

    Joint Director Prof. Xu Zhang, an Academician of Chinese Academy of Sciences, is the president of the Guangdong Institute of Intelligent Science and Technology. He also serves as the President of the Chinese Neuroscience Society, the Vice President of the Chinese Society of Cell Biology, the Vice President of the Pain Branch of the Chinese Medical Association and Director of Shanghai Brain-Intelligence Engineering Center.

    Joint Director Dr. Shuai Li is the founder and CEO of SIMR Biotechnology Co., Ltd. He is Shanghai Pujiang Talent Program Expert, Shanghai and Pujiang Biomedical Think Tank Expert. He received his Ph.D. in neuroscience at Institute of Neuroscience, Chinese Academy of Sciences in 2009, and published more than 10 SCI papers. Dr. Li has been deeply engaged in the novel drug development on chronic pain, inflammation and central nervous diseases. As the first responsible person, Dr. Li has obtained more than 30 million yuan research fundings and has been leading multiple translational drug development projects. One of his projects on chronic pain has entered international clinical phase I/II studies. Since the establishment in 2014, SIMR has 3 pipelines entered the clinical research stage and has applied for 14 clinical approvals based on independent innovative research projects. SIMR has filed 26 domestic and international patent applications, and 10 of them were licensed.

SIMR Biotechnology Co., Ltd

SIMR Biotechnology Co., Ltd is an innovation-oriented biopharmaceutical company dedicated to the discovery and development of new drugs for pain, epilepsy, depression, diabetic macular edema, Azheimer’s disease and other central nervous system related diseases. Since its establishment in 2014, the company has built up 8 clinical pipelines and applied for 17 domestic and international patents. The chronic pain product line has conducted clinical phase I and phase II studies in China,  Australia and the United States.   

SIMR website & WeChat public account

Website: http://simrbio.com/

WeChat Public Account: 塞默羅生(shēng)物(wù)